Ginsenoside Rb1 Interfered with Macrophage Activation by Activating PPARγ to Inhibit Insulin Resistance in Obesity.
Ding H., Dong J., Wang Y., Huang Q., Xu J., Qiu Z.
Laboratory Study on Type 2 Diabetes, Chronic Inflammation, published in Molecules (2023) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Molecules (2023)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 37049846
- PMCID
- PMC10096404
- DOI
- 10.3390/molecules28073083
- Citations
- 9
Abstract (original English)
Type 2 diabetes (T2D) is characterized by insulin resistance (IR), often accompanied by inflammation. Macrophage activation acts as an inflammatory response, which is characterized by macrophage recruitment in the initial stage. Ginsenoside Rb1 (Rb1) is a main active ingredient, which is known for its fat-reducing, anti-inflammatory effects. To clarify that Rb1 regulates macrophage activation in adipose tissue and improves tissue inflammation, network pharmacology and molecular docking were used for target prediction and preliminary validation. By constructing the co-culture model of adipose-derived stem cells (ADSC) and primary macrophage (PM), the body adipose tissue microenvironment was simulated to observe the adipogenesis degree of adipocytes under the effect of Rb1. The levels of cytokines, macrophage polarization, and protein or RNA expression in the inflammatory signaling pathway were finally detected. The results showed that 89 common targets of T2D-Rb1 were obtained after their intersection. Furthermore, according to the results of the KEGG pathway and PPI analysis, PTGS2 (COX-2) is the downstream protein of PPARγ-NF-κB. The molecular binding energy of PPARγ-Rb1 is -6.8 kcal/mol. Rb1 significantly inhibited the increase in MCP-1, TNF-α, and IL-1β induced by hypertrophic adipocytes supernatant and promoted the expression of IL-10. Rb1 inhibited the activation of inflam
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review
Systematic Review on Type 2 Diabetes, published in Stem Cell Rev Rep (2026) — summary generated from the PubMed abstract.
- 2026
Stem Cell Rev Rep2 citations - Level ASystematic ReviewEurope PMC
Dedifferentiation of Mature Adipocytes and Their Future Potential for Regenerative Medicine Applications
Systematic Review on Type 2 Diabetes, Chronic Wound, published in Biomedicines (2026) — summary generated from the PubMed abstract.
- 2026
Biomedicines - Level ASystematic ReviewEurope PMC
Consolidating Clinical Insights and Uncovering Novel Regulatory Mechanisms of Exosomal MicroRNAs in Obesity and Metabolic Dysfunction Associated Steatotic Liver Disease: A Systematic Review and Bioinformatics Analysis
Systematic Review on Type 2 Diabetes, Chronic Inflammation, published in Food Sci Nutr (2026) — summary generated from the PubMed abstract.
- 2026
Food Sci Nutr - Level AMeta-analysisEurope PMC
Autologous and allogeneic mesenchymal stem cell-based therapies for diabetes mellitus: A systematic review and meta-analysis
Meta-analysis on Type 2 Diabetes, Immune Modulation, published in World J Stem Cells (2025) — summary generated from the PubMed abstract.
- 2025
World J Stem Cells1 citations - Level ASystematic ReviewPubMed
Systematic Review: Exosomes as Molecular Messengers in the Development of Obesity-Related Complications in Children.
Systematic Review on Type 2 Diabetes, published in Curr Issues Mol Biol (2025) — summary generated from the PubMed abstract.
- 2025
Curr Issues Mol Biol - Level AMeta-analysisEurope PMC
Thiamine as a putative natural modulator of PPARγ: exploring a nutrient-based approach for type 2 diabetes
Meta-analysis on Type 2 Diabetes, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.
- 2025
Front Pharmacol